Medication Administration Protocol: 5-FLUOROURACIL

Document Control Information

Document ID:	MED-PROT-1170
Effective Date:	
Review Date:	2025-10-14
Therapeutic Class:	Adverse Event Report
Risk Level:	Critical

Standard Dosing Protocol

Current Standard Dose: Standard dosing per label
Monitoring Requirements: Standard warnings

Administration Guidelines

Route of Administration: IM
Frequency: As needed
Duration: 14 days
Patient Population: Patients similar to case: 2, age 47

Contraindications and Precautions

Contraindications: Enhanced screening for risk factors
Adverse Events: Ileus paralytic, Abdominal pain, Nausea

Detailed Clinical Considerations

Patient Monitoring Protocol

Regular monitoring is essential for safe administration of 5-FLUOROURACIL. Current protocols require Standard warnings. Healthcare providers should assess patient response and adjust therapy accordingly. Baseline laboratory values should be obtained prior to initiation. The mechanism of action involves 5-FLUOROURACIL mechanism with identified safety concern. Clinical efficacy has been demonstrated in Ileus paralytic, Abdominal pain, Nausea.

Special Populations

Elderly Patients: Dose adjustment may be required based on renal function and overall health status.
Pediatric Patients: Safety and efficacy not established in patients under 18 years.
Pregnancy: Use only if potential benefit justifies potential risk to fetus.
Nursing Mothers: Exercise caution when administering to nursing women.

Last revised: October 2023